Investigational drug · Phase 2
Aldoxorubicin HCl
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Pancreatic Cancer.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
11
Any phase or sponsor naming "Aldoxorubicin HCl"
First trial start
2020
Jul 21, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Aldoxorubicin HCl", any sponsor or status.
- Phase 210
Conditions studied
As listed on its trial records.
- Pancreatic Cancer
Approved drugs for the same conditions: Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Aldoxorubicin HCl" as an intervention, largest first.
- Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic CancerPivotal-lookingActive, not recruiting
ImmunityBio, Inc.Industry
NCT04390399 · 328 participants (planned) · Start Jul 21, 2020 · Primary completion Oct 13, 2025
Drug: N-803; Aldoxorubicin HCl and 7 more · For: Pancreatic Cancer
Sites: El Segundo, California; Newport Beach, California; East Brunswick, New Jersey · 4 sites in all
ImmunityBio, Inc.Industry
NCT01673438 · 15 participants · Start Jul 2012 · Primary completion Apr 2014
Drug: aldoxorubicin · For: Advanced Solid Tumor
Sites: Santa Monica, California
ImmunityBio, Inc.Industry
NCT03387085 · 9 participants · Start Mar 19, 2018 · Primary completion Sep 11, 2020
Drug: Aldoxorubicin HCl; N-803 and 15 more · For: Triple Negative Breast Cancer
Sites: El Segundo, California
- QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have ProgressedTerminated
ImmunityBio, Inc.Industry
NCT03387111 · 4 participants · Start Jan 9, 2018 · Primary completion Apr 17, 2019
Drug: Aldoxorubicin HCl; ETBX-011 and 18 more · For: Squamous Cell Carcinoma
Sites: El Segundo, California
ImmunityBio, Inc.Industry
NCT03387098 · 4 participants · Start Dec 28, 2017 · Primary completion Sep 12, 2018
Drug: Aldoxorubicin HCl; ALT-803 and 12 more · For: Pancreatic Cancer
Sites: El Segundo, California
ImmunityBio, Inc.Industry
NCT03586869 · 3 participants · Start Jul 17, 2018 · Primary completion Apr 17, 2019
Drug: Aldoxorubicin HCl; ALT-803 and 16 more · For: Pancreatic Cancer
Sites: El Segundo, California
ImmunityBio, Inc.Industry
NCT03563157 · 2 participants · Start Sep 28, 2018 · Primary completion Apr 21, 2019
Drug: Aldoxorubicin Hydrochloride; ALT-803 and 17 more · For: Colorectal Cancer Metastatic; mCRC
Sites: El Segundo, California
ImmunityBio, Inc.Industry
NCT03563144 · 0 participants · Start Aug 2018 · Primary completion Dec 30, 2019
Drug: Gemcitabine; Nab-paclitaxel and 17 more · For: Metastatic Pancreatic Cancer
Sites: El Segundo, California
ImmunityBio, Inc.Industry
NCT03554109 · 0 participants · Start Sep 2018 · Primary completion Jun 2020
Drug: Leucovorin; 5-Fluorouracil and 14 more · For: Triple Negative Breast Cancer (TNBC)
Sites: El Segundo, California
ImmunityBio, Inc.Industry
NCT03563170 · 0 participants · Start May 25, 2018 · Primary completion Aug 23, 2019
Drug: ETBX-011; GI-4000 and 15 more · For: Hepatocellular Carcinoma Non-resectable; Hepatocellular Carcinoma Recurrent
Sites: El Segundo, California
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Pancreatic Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- CadonilimabAK104Phase 331 trials
Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- AK117Phase 314 trials
Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- JAB-21822Glecirasib Citrate, KRAS G12C inhibitorPhase 310 trials
Allist Pharmaceuticals, Inc. · Non-small Cell Lung Cancer, KRAS P.G12C, Solid Tumor
- GEMPhase 35 trials
Shenzhen Majory Biotechnology Co., Ltd. · Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Cancer, Recurrent or Metastatic Cervical Cancer
- HRS-7058Phase 35 trials
Shandong Suncadia Medicine Co., Ltd. · KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment, Solid Tumors, Pancreatic Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.